ENTA实时信号 | 通过Getagraph.com最大化利润

购买 107264 min ago

@ $13.07

发出时间: 15 Feb 2024 @ 04:52

回报率: -5.32%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 4.73 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases...

Stats
今日成交量	65 645.00
平均成交量	226 817
市值	261.70M
EPS	$0 ( 2024-02-07 )
下一个收益日期	( $-1.330 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.880
ATR14	$0.0190 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Vance Terry	Buy	15 700	Stock Option (right to buy)
2024-03-06	Russell Lesley	Buy	15 700	Stock Option (right to buy)
2024-03-06	Peterson Kristine	Buy	15 700	Stock Option (right to buy)
2024-03-06	Hata Yujiro S	Buy	15 700	Stock Option (right to buy)
2024-03-06	Foletta Mark G	Buy	15 700	Stock Option (right to buy)

INSIDER POWER
70.25
Last 100 transactions
Buy: 1 263 491 \| Sell: 308 316

音量相关性

長: -0.06 (neutral)

短: -0.89 (strong negative)

Signal:(35.81) Neutral

Enanta Pharmaceuticals 相关性

10 最正相关
MODV	0.977
CNXC	0.977
SBSI	0.975
NURO	0.975
HMST	0.974
TRVG	0.971
NWL	0.97
INDB	0.97
FSFG	0.97
TBNK	0.97

10 最负相关
AGGR	-0.983
TBSA	-0.983
LEGA	-0.982
ACQR	-0.981
AHRN	-0.977
FRON	-0.976
LGAC	-0.976
FRSG	-0.975
HERA	-0.975
CFIV	-0.975

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Enanta Pharmaceuticals 相关性 - 货币/商品

-0.08
( neutral )

-0.13
( neutral )

0.00
( neutral )

-0.22
( neutral )

0.63
( weak )

0.16
( neutral )

Enanta Pharmaceuticals 财务报表

Annual	2023
营收:	$79.20M
毛利润:	$76.83M (97.01 %)
EPS:	$-6.38

FY	2023
营收:	$79.20M
毛利润:	$76.83M (97.01 %)
EPS:	$-6.38

FY	2022
营收:	$86.16M
毛利润:	$83.19M (96.55 %)
EPS:	$-5.91

FY	2021
营收:	$97.07M
毛利润:	$0.00 (0.00 %)
EPS:	$-3.92

Financial Reports:

No articles found.

Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.